Press Releases

Date Title  
Toggle Summary amedes und Natera bieten gemeinsam nicht-invasiven Test für die Pränataldiagnostik in Deutschland an
Ab sofort wird die amedes Gruppe den Natera-Test für nicht-invasive Pränataldiagnostik in Deutschland vertreiben. amedes, bundesweit tätiger diagnostischer Dienstleister, teilte heute den Vertragsabschluss mit der US-amerikanischen Diagnostikfirma mit. Der Panorama TM – Test wird bereits in den USA
Toggle Summary Natera Completes $54.6 Million Financing to Support Expansion, Continued Global Rollout of Non-Invasive Prenatal Test Panorama™
Financing Adds Leading Growth Stage Investors to Existing Syndicate Natera today announced that it has completed a $54.6 million financing round to support the expansion and continued global rollout of Natera’s non-invasive prenatal test, Panorama™. The financing round included two new lead
Toggle Summary Data Published in Prenatal Diagnosis Demonstrate Panorama’s Ability to Accurately Detect Chromosomal Abnormalities
Blinded, Independent Study Shows Proprietary Technology Accurately Detected Trisomy 21, Trisomy 13, Trisomy 18, Monosomy X and Triploidy The Fetal Medicine Foundation and Natera today announced the publication of data in Prenatal Diagnosis demonstrating the high accuracy of Natera’s non-invasive
Toggle Summary ARUP Laboratories Announces Availability of Natera's Non-Invasive Prenatal Test, Panorama™
ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory, and Natera, a leading innovator in reproductive and prenatal genetic testing, today announced that Natera's non-invasive prenatal screening test, Panorama™, is available to ARUP clients nationwide.
Toggle Summary Bio-Reference Laboratories, Inc. Will Offer Non-Invasive Prenatal Testing (NIPT) From Natera
Bio-Reference Laboratories, Inc. (BRLI) announced today that the Company and Natera have entered into a definitive agreement to commercialize the Panorama(TM) non-invasive prenatal screening test developed by Natera. The Panorama test will be sold by the GenPath business unit of Bioreference.
Toggle Summary Quest Diagnostics to Provide Nationwide Access to Natera’s New Non-Invasive Prenatal Test
Quest Diagnostics (NYSE:DGX), the world’s leading diagnostic information services company, and Natera, a leading innovator in prenatal genetic testing, today announced that Quest Diagnostics will offer physicians access to Panorama™, a new non-invasive prenatal test developed by Natera.
Toggle Summary Natera Launches Non-Invasive Prenatal Test Panorama™ with Best-in-Class Sensitivity, Specificity for Detection of Fetal Chromosomal Abnormalities
Panorama’s clinical validation data was presented live at the annual Society of Maternal Fetal Medicine Meeting on February 15, 2013. Natera, a leading innovator in reproductive and prenatal genetic testing, today announced that the company’s non-invasive prenatal screening test, Panorama™, will
Toggle Summary Validation Data Presented by Natera Demonstrates Best-in-Class Specificity and Sensitivity of Non-Invasive Prenatal Test Panorama™
Data Presented at Society for Maternal-Fetal Medicine Annual Meeting Natera today announced the presentation of validation data demonstrating unmatched specificity and sensitivity of the company's non-invasive prenatal test, Panorama(TM). The presentation, titled "Use of targeted sequencing of SNPs

Footer disclaimer

Footer disclaimer

© Natera 2019. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.